As part of our mission to address drug promiscuity, we are committed to encouraging the translation of our advancements into new treatments. We pursue milestone-driven projects focused on the optimization and preclinical testing of lead therapeutics based on the ESiNAR-X^® platform across various diagnoses so that there is sufficient scientific evidence to justify filing of regulatory approval.